Regulatory Issues in the Therapeutic Use of Stem Cells by Deasy, Bridget M. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 9
Regulatory Issues in the Therapeutic Use of Stem Cells
Bridget M. Deasy, Jordan E. Anderson and
Shannon Zelina
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55945
1. Introduction
1.1. Stem cell tourism
Advances in stem cell research and media publicity of stem cell potential have raised the
hopes of patients with severe disabilities and conditions which lack a cure.  While stem-
cell-based therapies are the clinical standard of care for a few conditions, such as leuke‐
mia and more recently for some burns and corneal disorders, stem cell tourism continues
to rise worldwide.
Unfortunately, clinics around the world are exploiting patients’ hopes by offering supposed
stem cell therapies, without credible scientific rationale, oversight or patient protections.
Occurring particularly in Asia and South America, treatments which are illegal in most
counties are being offered for what are often considered incurable conditions, such as brain
tumors, congestive heart failure or chronic obstructive pulmonary disease. In addition,
countless other conditions are listed as candidates by these clinics including eye disease or
orthopedic injuries or disease. In response to this, the International Society for Stem Cell
Research (ISSCR) released “The Guidelines for the Clinical Translation of Stem Cells” which called
for rigorous standards in the development of stem cell therapies and outlining what needs to
be accomplished to move stem cells from promising research to proven treatments[1]. The goal
of ISSCR in shining this light on the dangers of stem cell tourism is to ensure that the promise
of stem cell research is delivered to patients in a safe, effective and fair manner. A number of
professional organizations have also published guidance documents for the responsible
conduct in translational stem cell research.
The  general  public  receives  information  regarding  stem  cell  potential  from  mainstream
media and does not fully understand the risks associated with unproven treatments. In the
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most desperate situations,  patients  may see no other options,  or  may view the years of
continuing research as an obstacle to their potential cure. Yet, untested treatments can be
dangerous and years of preclinical and clinical research are required to determine which
novel stem-cell based therapies are effective and safe. In one example, brain tumors were
discovered in a 9-year old boy who travelled to Russia to receive stem cell treatments to
his brain; later it was found that the tumors were the result of cells from at least 2 different
donors [2]. Even carefully planned and approved studies can go wrong and have unfortu‐
nate results, as in the fatal gene therapy case of Jesse Gelsinger, who received experimen‐
tal therapy at University of Pennsylvania[3, 4].
Lau et al reported on the clinics around the world that are exploiting patients’ hopes by
professing to have effective stem cell therapies for seriously ill patients. These therapies often
carry a hefty pricetag. However, they occur in counties which have limited oversight and allow
treatment to occur in the absence of credible scientific rationale, transparency, oversight, or
patient protections [5].
Comprehensive government regulations exist in the US, and several other countries. Below,
we describe the U.S. and other government regulations associated with the use of human stem
cell and tissues in regenerative medicine.
2. Cell Products must follow FDA regulatory guidelines
2.1. FDA’s risk-based approach
To protect the public from risks associated with cell therapies and demonstrate the effective‐
ness of treatments, the U.S. FDA and other professional societies such as the ISSCR, and the
United States Pharmacopia (USP), have established guidelines for therapies using human
cellular and tissue-based products (HCT/Ps). The FDA has statutory authority to prevent the
spread of communicable diseases granted under Section 361 of the Public Health Service Act
(PHS Act, 42 U.S.C. § 264). HCT/Ps are regulated through a risk-based approach outlined
predominantly in 21 C.F.R. Part 1271. Some HCT/Ps are regulated solely under Part 1271 while
other HCT/Ps are regulated under both Part 1271 and FDA’s Federal Food, Drug, and Cosmetic
Act (FDCA, premarket and post- market regulation of medical devices and drugs), & section
351 of the PHS Act for biological products. FDA's regulation focuses on three general areas: 1)
limiting the risk of transmission of communicable disease from donors to recipients; 2)
establishing manufacturing practices that minimize the risk of contamination; 3) requiring an
appropriate demonstration of safety and effectiveness for cells and tissues that present greater
risks due to their processing or their use [6, 7].
Stem  cell  therapies  show  excellent  promise  for  many  types  of  treatments.  However,
scientific,  manufacturing and safety challenges exist.  Once the optimal  stem cell  type is
identified  for  a  given  treatment  (Table  1),  there  is  a  requirement  to  demonstrate  the
product’s  safety  and efficacy  in  a  clinical  setting.  Cell  therapies  must  overcome several
challenges before they can be considered safe for human use. First, most cell therapies will
Regenerative Medicine and Tissue Engineering204
require  large  numbers  of  cells.  Large  cell  doses  are  obtained by  increasing  cell  harvest
yields and by increasing ex vivo expansion yields. As cell cultures are expanded over long
time periods, they show signs of aging that may be similar to human aging [8, 9]. Lengthy
expansion  periods  can  result  in  ineffective  cellular  products[10].  Cells  may  also  be
manipulated  in  other  manufacturing  steps  that  include  cell-selection  processes,  genetic
modifications, or encapsulation with another biological device. Cells that undergo ex vivo
manipulation  may  lose  potency,  or  acquire  infectious  contaminants,  or  become  trans‐
formed /  tumorogenic due to the cell  culture conditions [11,  12].  Finally,  the cells them‐
selves may pose a risk, simply due to the novelty of the therapy and unknowns associated
with their behavior in the body.
Embryonic Stem Cells Adult iPS Adult BM-MSCs Adult Adipose MSC
Ethical concerns [56-60] [61-67]
Tumorogenic [68-72] [59, 73-75] [76-79]
Scale-Up challenge [80-83] [84-86] [87]
Genetically unstable [88, 89] [34, 39, 90-94] [95]
Immunogenic difficulties [96, 97] [37, 98]
Table 1. Scientific and Manufacturing Challenges in Stem Cell Sourcing ( numbers refer to literature references) Several
stem cell types are studied for their potential use in regenerative medicine, including, but not limited to, embryonic
stem cells [20-27], inducible pluripotent stem cells [28-41], bone-marrow stem cells [42-46] and adipose-derived stem
cells [47-55]. However, there are challenges with all stem cell types. A major concern with clinical application of iPSCs
is their tendency to form tumors and cause cancer. Both ESC and iPSCs form teratoma in vivo, a major obstacle to
stem-cell based regenerative medicine by the FDA. Also they are ethically controversial since they require genetic
engineering using oncogenes. More recently, proteins have been used to generate piPSCs but the conversion
efficiency us quite low. Adult derived BM-MSCs or adipose MSC are limited by their expandability.
In 1993, the US FDA began establishing regulatory and guidance documentation for cell
therapies with the issuance of Application of Current Statutory Authority to Human Somatic
Cell-therapy and Gene-therapy Products [13] which provided a biologics regulatory frame‐
work for the use of HCT/Ps. Table 2 provides a list of other key regulatory and guidance
documents. The tiered risk-based approach means that products which present a lower
perceived risk will be less regulated, while products with a larger perceived risk will undergo
more extensive controls and examination. Both will require the cell products to be manufac‐
tured following Good Manufacturing Practices (GMP), and Good Tissue Practices (GTP).
Additional regulatory requirements will depend on whether the cell product is minimally
manipulated or more-than-minimally manipulated.
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Guidance for Industry: Guidance for human somatic cell therapy and gene
therapy 1998
GMPs GMP 2001
Suitability determination for donors of HCT/Ps; proposed rule
GTP
1999
Current good tissue practice for manufacturers of HCT/Ps;
inspection and enforcement; proposed rule 2001
Human cells, tissues and cellular and tissue-based products
(HCT/Ps); establishment registration and listing; final rule 2001
Good clinical practice, GCP, ICH E6
GCP
1996
Validation of procedures for processing of human tissues
intended for transplantation: final guidance 2002
Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and
Cellular and Tissue-Based Products 2007
Guidance for Industry Potency Tests for Cellular and Gene Therapy Products 2011
Table 2. Key US FDA Regulatory and Guidance Documents. Over the past 15 years, the FDA has provided several
guidance documents for HCT/Ps. A few products such as Genezyme’s Carticel received approval prior to the issuance
of these documents and has been grandfathered in. Many of these guidance documents are issued by CBER, the
center within FDA that regulates biological products for human use following applicable federal laws, including the
Public Health Service Act and the Federal Food, Drug and Cosmetic Act.
Minimal manipulation is defined by the FDA for cells or nonstructural tissue as processing
that does not alter relevant biological characteristics of cells or tissues. HCT/Ps that meet 1271
criteria for regulation solely under section 361 of the PHS Act and the regulations in Part 1271
are called “361 HCT/Ps”, and are not subject to any premarket review requirements. The Center
for Biologics Evaluation and Research (CBER) has jurisdiction over 361 HCT/Ps.
According to 21 CFR 1271.10, minimal manipulation criteria include:
1. The HCT/P is minimally manipulated;
2. The HCT/P is intended for homologous use only, as reflected by the labeling, advertising,
or other indications of the manufacturer’s objective intent;
3. The manufacture of the HCT/P does not involve the combination of the cell or tissues with
another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent,
provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage
agent does not raise new clinical safety concerns with respect to the HCT/P; and
4. Either:
i. The HCT/P does not have a systemic effect and is not dependent upon the metabolic
activity of living cells for its primary function; or
ii. The HCT/P has a systemic effect or is dependent upon the metabolic activity of living
cells for its primary function, and:
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a. is for autologous use;
b. is for allogeneic use in a first-degree or second-degree blood relative; or
c. is for reproductive use.
For cells, minimal manipulation means processing that does not alter the relevant biological
characteristics of cells or tissues. Examples of products regulated as 361 HCT/Ps include bone
marrow or blood transplants and organ transplants.
HCT/Ps that do not meet one or more of the four major criteria, are considered more-than-
minimally- manipulated HCT/P. FDA has stated that density-gradient separation, cell
selection, centrifugation, and cryopreservation constitute minimal manipulation. All processes
that manipulate the cell / tissue product such as cell activation, encapsulation, ex vivo
expansion, and gene modifications are considered more-than-minimal manipulations. Most
advanced cellular therapies meet criteria for the more-than minimally manipulated category
[14]. Finally, it is possible to request an informal jurisdictional determination on the level of
manipulation from the Tissue Reference Group (TRG), or submit a formal Request for
Designation (RFD) from the Office of Combination Products (OCP). Figure 1 is a schematic of
regulatory pathway assessment to determine which guidelines apply to a given HCT/Ps
product.
2.2. Manufacturing of HCT/Ps requires GTPs
For HCT/Ps that do not meet the criteria established in Section 1271.10, FDA premarket review
is required; this includes obtaining FDA license, approval, or clearance.
All steps in the manufacturing of HCT/Ps will require compliance with Current Good Tissue
Practice (cGTPs). cGTPs cover manufacturing facilities and processes. The manufacturing
process can be broadly described as 1) procurement of HCT/Ps (donor screening and testing,
product recovery), 2) processing of HCT/Ps (tissue or cell recovery /isolation, product han‐
dling, product labeling), 3) storage (e.g. cryopreservation), and 4) distribution. Many of these
steps are common to GTPs and GMPs with the goal of safe and effective products via well-
controlled processes and thorough supporting documentation. Requirements for standard
operating procedures (SOPs), labeling controls, and storage requirements also exist.
2.2.1. Procurement
Therapies with HCT/Ps will require a determination of donor eligibility. For the FDA, donor
eligibility is determined based on donor screening and testing for relevant communicable
disease agents and diseases, and is required for all donors of cells or tissue used in HCT/Ps,
with some exceptions listed in C.F.R. Part 1271.90.
As part of clinical or industry compliance with donor testing requirements, procedures to
process, store, label, and package cell products also are needed. Hospitals and companies
involved in cell/tissue therapeutics manufacturing must establish quality programs which
consist of a comprehensive system for manufacturing and tracking HCT/Ps. The quality
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program must follow CGTP requirements, and be designed to prevent, detect, and correct
deficiencies that may lead to circumstances that increase the risk of introduction, transmission,
or spread of communicable diseases.[6, 7]
2.2.2. Processing
The implementation of a Quality Assurance (QA) program includes principles of good
manufacturing practice (GMP) and a quality control (QC) system. A QC system is required to
ensure safety and efficacy of cell applications. GMP regulations apply to all phases of cell/
tissue collection, processing and expansion, and storage. GMP quality practices are required
for HCT/Ps to be used for clinical procedures and INDs. A compliant quality program for
record and process control is a critical part of a QC system.
A compliant material control program is essential for FDA licensure. During review of new
license applications, clinics and companies are asked to provide detailed descriptions of the
manufacturing process and documentation of source country for all materials of animal origin.
Additionally, for FDA-regulated products intended for administration to humans, companies
must minimize any chance that BSE could be introduced into products during the manufac‐
turing process and ensure that all materials are used as intended in the processing and are
contamination free. Subsequently, a program for control of materials used in the process is
necessary to meet FDA compliance and product safety.
2.2.3. Storage
If the HCT/P product involves cryopreservation, then compliance requires that the process
includes an understanding of the shelf-life and how the freezing & storage process affects the
HCT/Ps to complete the quality testing program. Banked cells should be stored under
conditions shown to be suitable for long-term stability. Cell/tissue stability under the freezing
and storage conditions should be validated using cell recovery or viability data. It is expected
that establishment of a stability program for a banking process will lead to the development
of quality products over a long term storage period and provide confidence that they will be
effective in clinical applications.
2.2.4. Distribution testing
For the lot release of patient’s cells/tissues for clinical use, standards for in-process and final
product quality must be established. Specifically for FDA licensure, companies must submit
their facility controls, process controls, and product standards designed with scientific
principles to ensure the safety and effectiveness of all HCT/Ps products. This again is based
on SOPs and controls for adherence to the cGTP, Current Good Manufacturing Practice (cGMP)
and 21 CFR 1271 requirements. Product lot release specifications ensure that all products are
produced in a safe and consistent manner and should be effective in clinical applications. In
order to meet HCT/Ps regulations, product lot release specification should include testing for
cell phenotype to confirm purity, potency, and identity.
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The application for licensure requires that companies demonstrate that the HCT/P product
standards and procedures are based on good science, and thorough and extensive data. A
comprehensive product characterization program is needed to understand the products and
how they may be clinically beneficial. During the application process, the FDA may request
that the hospital or company applicant expand on a concept or further explain the rationale/
approach or provide additional data. FDA premarket review and licensing is considered a
lengthy and arduous process, however new products applicants may benefit by the recent
approvals of several cell-based products (Table 3).
Product
(Company)
Condition Cell Type Approval
Carticel
(Genzyme BioSurgey)
Articular cartilage
damage in the knee
Autologous chondrocytes (adult/
differentiated)
US FDA approval 1997
(grandfathered in)
Apligraf(Organogenisis) Diabetic foot ulcers
and venous leg ulcers
Neonatal foreskin allogeneic
keratinocytes and fibroblasts in
bovine collagen scaffold
US FDA approval 1998
Provenge
(Dendreon)
Asypmptomatic or
hormone refractory
prostate cancer
Autologous dendritic cells (adult/
differentiated)
US FDA approval 2010
Gintuit
(Organogenesis)
Asypmptomatic or
hormone refractory
prostate cancer
Autologous dendritic cells (adult/
differentiated)
US FDA approval 2010
La Viv
(Fibrocell Science inc)
Moderate to severe
nasolabial fold
wrinkles
Autologous fibroblasts (adult/
differentiated)
US FDA approval 2012
ChondroCelect®
(TiGenix)
Single symptomatic
cartilage defects in
the knee
Autologous chondrocytes (adult/
differentiated)
EMEA approval 2009
Prochymal
(Osiris)
Graft vs. host disease
in children who are
refractory to steroid
therapy post-BMT
Allogeneic mesenchymal stem cells
from donor bone marrow
Health Canada/New
Zealand grant
conditional approval
2012
Hearti-cellgram-AMI
(FCB-Pharmicell)
Heart repair post-
myocardial infarction
Autologous bone marrow-derived
mesenchymal stem cells
Korean approval 2011
Cartistem
(Medipost)
Traumatic and
degenerative
osteoarthritis
Allogeneic mesenchymal stem cells
from donor umbilical cord blood
Korean approval 2012
Cupistem
(Anterogen)
Anal fistula in Crohn’s
Disease
Autologous fat-derived ‘stem cells’ Korean approval 2012
Table 3. Approved Cell Therapy Products by the U.S. FDA and non-3rd World Countries. Several cell products have
received US approval[99] and are in current use for a number of patients. Most US approved products are for
autologous use, only Apilgrafs foreskin cells are used allogeneically. Osiris recently received conditional approval for
allogeneic use of mesenchymal stem cells in pediatric graft-vs-host disease.
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3. Non-U.S. regulatory systems
The European Union, Australia and Canada and other countries have established similar
regulatory systems for the use of post-natal human HCT/Ps.
The European Medicines Agency (EMEA) is the regulating body with authorization and
supervision of cell therapy products and other “advanced therapy medicinal products” [15].
As of January 2011, the EMA’s Committee for Advanced Therapies (CAT) recognized the
potential of stem cell therapies and released a reflection paper to work in conjunction with the
Guideline on Human Cell-based Medicinal Products (EMEA/CHMP/410869/2006) for the Market‐
ing Authorization Application (MA). Both the reflection paper and the guidance detail the
quality and manufacturing, non-clinical, and clinical aspects required for MA approval. The
quality and manufacturing considerations include starting and raw materials, manufacturing
process, quality control, validation of the manufacturing process, development pharmaceutics,
traceability and biovigilance, and comparability. Pharmacology and toxicology are the non-
clinical development aspects to be considered. From a clinical development standpoint,
general aspects, pharmacodynamics, pharmacokinetics, dose finding studies, clinical efficacy,
clinical safety,pharmacovigilance, and risk management plans are necessary for approval.
In Australia, HCT/Ps or products (biologicals) are regulated by the Therapeutic Goods
Administration (TGA) which is the Australian equivalent to the FDA. Similar to the FDA
approach, the TGA’s regulatory framework for biological imposes varying levels of regulation
on the therapy or product depending on risk, extent of manipulation, and whether the intended
use of the biological is its usual biological function[16]. In order to gain approval a treatment that
used a biological, and the biologicals intended use was not its normal function, a hospital or
company would be required to submit substantial evidence that the particular therapy or
product is safe, effective and of high quality.
In order for a stem cell therapy to be approved by Health Canada it must meet the regulations
as stated in the Safety of Human Cells, Tissues and Organs for Transplantation Regulations
(CTO Regulations[17]). The CTO Regulations detail requirements to ensure safety in process‐
ing; storage; record keeping; distribution; importation; error, accident and adverse reaction
investigation and reporting. Requirements for donor screening, testing, and suitability
assessment are described in the processing regulations as well as the testing and measurements
performed on the products after retrieval or in preparation for use, preservation, or packag‐
ing[17].
Health Canada, the FDA equivalent in Canada, is the first approving body in the world to
approve a manufactured stem cell based drug intended to treat a systemic disease -acute Graft
versus Host Disease (aGvHD) [18]. Osiris Therapeutics of Columbia, Maryland developed
Prochymal [remestemcel-L, adult human mesenchymal stem cells (hMSCs) for intravenous
infusion], a liquid cell suspension of ex vivo cultured adult MSCs derived from the bone
marrow of healthy adult donors. Prochymal is the first stem cell therapy approved for clinical
use in patients, specifically pediatric patients. Health Canada required Osiris to continue a
Risk Management Plan to demonstrate that the benefits of Prochymal continue to outweigh
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risk, the addition of post-market studies, and maintenance of a treated patient registry for
approval[19].
Table 3 provides a list of cell therapy products that have received U.S. FDA approval or other
government approval. Despite extensive stem cell research over the past 15 years, most cell
products are not stem cell derived. Only Osiris’ BM-MSC product and 3 Korean products are
stem cell based products.
4. Conclusions
This report examines the different processes involved in HCT/Ps manufacturing and high‐
lights the guidelines that must be followed to obtain FDA or other country specific regulatory
approval. Ex vivo expansion, cell selection or gene modification will likely be necessary for
most advanced cell and tissue therapies. These modifications increase the risk associated with
the treatment and render the product to be regulated under a higher risk category of more-
than-minimally-manipulated product. Key to biomanufacturing is the implementation of a
QA/QC program including a quality control system and GMP principles which apply to all
phases of manufacturing.
Figure 1. Regulatory Pathway Assessment If an HCT/Ps product is minimally manipulated it is regulated as a “361
HCT/Ps”, and it is not subject to any premarket review requirements. However, if the HCT/Ps is more-than-minimally
manipulated, and does not qualify for exemptions under 21 CFR 1271.15, it will be regulated as drug, device and/or
biologic product under 351 of the PHS Act.
Many counties actively regulate the use of stem cell products, however, there are still a
number of areas around the world that have little regulations and unregulated treatments
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pose risk to patients and the careful development of the field. The current challenge to deliv‐
er safe cell and tissue therapies and curb unregulated treatments may soon apply to gene
therapy and other innovative technologies. Early government regulation and active educa‐
tion by a number of professional organizations should reduce the spread of medical tourism
and aid in the development of safe and effective treatments in the field of regenerative med‐
icine.
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